Drug Approval | August 30, 2024
Natco Pharma announces submission of TABRECTA to USFDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States
The brand will establish an integrated hearing care ecosystem at Neuberg Diagnostics centers across the length and breadth of the country
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
Subscribe To Our Newsletter & Stay Updated
